Cancer imaging by optical coherence tomography: Preclinical progress and clinical potential

Nature Reviews Cancer

Volumn 12, Issue 5, 2012, Pages 363-368

  Vakoc, Benjamin J ^a,b   Fukumura, Dai ^a   Jain, Rakesh K ^a   Bouma, Brett E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANGIOGRAPHY; CANCER RESEARCH; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ECHOGRAPHY; EPIFLUORESCENCE MICROSCOPY; ESOPHAGUS CARCINOMA; HUMAN; IN VIVO STUDY; LYMPHANGIOGRAPHY; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHOTOACOUSTICS; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT; WHOLE BODY IMAGING; X RAY ABSORPTION SPECTROSCOPY;

ANIMALS; ANTINEMATODAL AGENTS; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84860217696     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3235     Document Type: Review

References (49)

1. Huang, D. et al. Optical coherence tomography. Science 254, 1178-1181 (1991). (Pubitemid 21917444)
2. Bouma, B. E., Yun, S.-H., Vakoc, B. J., Suter, M. J. & Tearney, G. J. Fourier-domain optical coherence tomography: recent advances toward clinical utility. Curr. Opin. Biotechnol. 20, 111-118 (2009).
3. Wojtkowski, M. High-speed optical coherence tomography: basics and applications. Appl. Opt. 49, D30-D61 (2010).
4. Zysk, A. M., Nguyen, F. T., Oldenburg, A. L., Marks, D. L. & Boppart, S. A. Optical coherence tomography: a review of clinical development from bench to bedside. J. Biomed. Opt. 12, 051403 (2007).
5. Gabriele, M. L. et al. Optical coherence tomography: history, current status, and laboratory work. Invest. Ophthalmol. Vis. Sci. 52, 2425-2436 (2011).
6. Suter, M. J. et al. Intravascular optical imaging technology for investigating the coronary artery. JACC. Cardiovasc. Imaging 4, 1022-1039 (2011).
7. Leunig, M. et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 52, 6553-6560 (1992).
8. Brown, E., Munn, L. L., Fukumura, D. & Jain, R. K. In vivo imaging of tumors. Cold Spring Harb. Protoc. 2010 (doi:10.1101/pdb.prot5452).
9. Hak, S., Reitan, N., Haraldseth, O. & de Lange Davies, C. Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles. Angiogenesis 13, 113-130 (2010).
10. Vakoc, B. J. et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nature Med. 15, 1219-1223 (2009).
11. Winkler, A. et al. In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model. Mol. Imaging Biol. 13, 1173-1182 (2010).
12. Winkler, A., Rice, P., Drezek, R. & Barton, J. Quantitative tool for rapid disease mapping using optical coherence tomography images of azoxymethane-treated mouse colon. J. Biomed. Opt. 15, 041512 (2010).
13. Jugold, M. et al. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice. Eur. Radiol. 18, 753-758 (2008).
14. Badea, C. T., Drangova, M., Holdsworth, D. W. & Johnson, G. A. In vivo small-animal imaging using micro-CT and digital subtraction angiography. Phys. Med. Biol. 53, R319-R350 (2008).
15. Condeelis, J. & Weissleder, R. In vivo imaging in cancer. Cold Spring Harb. Perspect. Biol. 2, a003848 (2010).
16. Yoshioka, K. et al. A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. Biochim. Biophys. Acta 1289, 5-9 (1996). (Pubitemid 26075665)
17. O'Neil, R., Wu, L. & Mullani, N. Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol. Imaging Biol. 7, 388-392 (2005). (Pubitemid 44193403)
18. Sheth, R. A., Josephson, L. & Mahmood, U. Evaluation and clinically relevant applications of a fluorescent imaging analog to fluorodeoxyglucose positron emission tomography. J. Biomed. Opt. 14, 064014-064018 (2009).
19. Nitin, N. et al. Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. Int. J. Cancer 124, 2634-2642 (2008).
20. Corish, P. & Tyler-Smith, C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng. 12, 1035-1040 (1999). (Pubitemid 30011478)
21. Elliott, G., McGrath, J. & Crockett-Torabi, E. Green fluorescent protein: a novel viability assay for cryobiological applications. Cryobiology 40, 360-369 (2000). (Pubitemid 30666410)
22. Baumstark-Khan, C. et al. Green Fluorescent Protein (GFP) as a marker for cell viability after UV irradiation. J. Fluoresc. 9, 37-43 (1999). (Pubitemid 129755469)
23. Chung, E. et al. Secreted gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4, e8316 (2009).
24. Hagendoorn, J. et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 66, 3360-3364 (2006).
25. Jain, R. K. Taming vessels to treat cancer. Sci. Am. 298, 56-63 (2008). (Pubitemid 351182556)
26. Isaka, N., Padera, T., Hagendoorn, J., Fukumura, D. & Jain, R. K. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 64, 4400-4404 (2004). (Pubitemid 38856908)
27. Jung, Y., Zhi, Z. & Wang, R. Three-dimensional optical imaging of microvascular networks within intact lymph node in vivo. J. Biomed. Opt. 15, 050501-050503 (2010).
28. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
29. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
30. Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887 (2011).
31. Hu, S. & Wang, L. V. Photoacoustic imaging and characterization of the microvasculature. J. Biomed. Opt. 15, 011101 (2010).
32. Wang, L. V. Multiscale photoacoustic microscopy and computed tomography. Nature Photonics 3, 503-509 (2009).
33. Su, J. L. et al. Advances in clinical and biomedical applications of photoacoustic imaging. Expert Opin. Med. Diagn. 4, 497-510 (2010).
34. Li, M.-L. et al. Simultaneous molecular and hypoxia imaging of brain tumors in vivo using spectroscopic photoacoustic tomography. Proc. IEEE 96, 481-489 (2008).
35. Brown, E. et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Med. 7, 864-868 (2001). (Pubitemid 32691644)
36. Boppart, S. A., Oldenburg, A. L., Xu, C. & Marks, D. L. Optical probes and techniques for molecular contrast enhancement in coherence imaging. J. Biomed. Opt. 10, 041208 (2005).
37. de Boer, J. & Milner, T. Review of polarization sensitive optical coherence tomography and Stokes vector determination. J. Biomed. Opt. 7, 359-371 (2002).
38. Farhat, G., Mariampillai, A., Yang, V. X. D., Czarnota, G. J. & Kolios, M. C. Detecting apoptosis using dynamic light scattering with optical coherence tomography. J. Biomed. Opt. 16, 070505 (2012).
39. Sufan, R. et al. Oxygen-independent degradation of HIF-α via bioengineered VHL tumour suppressor complex. EMBO Mol. Med. 1, 66-78 (2009).
40. Skala, M., Fontanella, A., Lan, L., Izatt, J. & Dewhirst, M. Longitudinal optical imaging of tumor metabolism and hemodynamics. J. Biomed. Opt. 15, 011112 (2010).
41. Standish, B. et al. Interstitial doppler optical coherence tomography as a local tumor necrosis predictor in photodynamic therapy of prostatic carcinoma: an in vivo study. Cancer Res. 68, 9987-9995 (2008).
42. Standish, B. A. et al. Interstitial Doppler optical coherence tomography monitors microvascular changes during photodynamic therapy in a Dunning prostate model under varying treatment conditions. J. Biomed. Opt. 12, 034022 (2007).
43. Standish, B. A. et al. in Gastrointestinal Endoscopy 326-333 (Mosby Yearbook, 2007).
44. Li, H. et al. Feasibility of interstitial Doppler optical coherence tomography for in vivo detection of microvascular changes during photodynamic therapy. Lasers Surg. Med. 38, 754-761 (2006). (Pubitemid 44522031)
45. Pircher, A. et al. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int. J. Mol. Sci. 12, 7077-7099 (2011).
46. Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nature Rev. Clin. Oncol. 6, 327-338 (2009).
47. Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817-2823 (2010).
48. Sorensen, A. G. et al. A "Vascular Normalization Index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296-5300 (2009).
49. Sorensen, A. G. et al. Increased survival of glioblastoma patients who respond to anti-angiogenic therapy with elevated blood perfusion. Cancer Res. 72, 402-407 (2012).